For placebo , golimumab @ mg and golimumab @ mg , respective adverse event incidences/@ pt-yrs ( @ % CIs ) up to wk @ were : @ ( @ to @ ) , @ ( @ to @ ) , @ ( @ to @ ) for death ; @ ( @ to @ ) , @ ( @ to @ ) , @ ( @ to @ ) for serious infection ; @ ( @ to @ ) , @ ( @ to @ ) , @ ( @ to @ ) for tuberculosis ; @ ( @ to @ ) , @ ( @ to @ ) , @ ( @ to @ ) for opportunistic infection ; @ ( @ to @ ) , @ ( @ to @ ) , @ ( @ to @ ) for demyelination ; and @ ( @ to @ ) , @ ( @ to @ ) , @ ( @ to @ ) for lymphoma .